Docket No. 251529US96DIV

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Michael R. JOHNSON

SERIAL NO: New Application

FILED: He

Herewith

FOR:

SODIUM CHANNEL BLOCKERS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR

Applicant(s) wish to disclose the following information.

REFERENCES

| The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed |
|---|
| references were filed in prior application Serial No. 10/076,551, filed February 19, 2002, where required, as are |
| either statements of relevancy or any readily available English translations of pertinent portions of any non-English |
| language references. |

☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

| Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present |
|---|
| application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) |
| is attached along with PTO 1449. |

☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

| Each item of information contained in this information disclosure statement was first cited in any communication |
|---|
| from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of |
| this statement |

□ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number <u>15-0030</u>. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

James J. Kel

Registration No. 41,504

Customer Number

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

| *Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in | Form PTO 1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE | | | ATTY DOCKET NO. 251529US96DIV | | | SERIAL NO. New Application | | | |
|--|--|--------------|----------------------|----------------------------------|--------------------|-------------------------|-----------------------------|-------------|----------|--------------------|
| Name | LIST OF | REFE | RENCES CITED BY APPL | .ICANT | | | | NSON | | |
| EXAMINER NUMBER DATE NAME CLASS SUB FILING DATE | | | | | | Herewith | | GROUP | | |
| NAME | | | | | U.S. PATENT DO | CUMENTS | · | | | |
| AB 3,794,734 02-26-74 Cragoe, Jr. et al. AC 3,864,401 02-04-75 Schulz et al. AD 3,914,263 10-21-75 Cragoe, Jr. et al. AE 3,929,872 12-30-75 Cragoe, Jr. et al. AF 3,931,239 01-06-76 Cragoe, Jr. et al. AF 3,931,239 01-06-76 Cragoe, Jr. et al. AG 3,953,476 04-27-76 Cragoe, Jr. et al. AG 3,953,476 04-27-76 Cragoe, Jr. et al. AI 3,966,966 06-29-76 Cragoe, Jr. et al. AI 4,006,180 02-01-77 Cragoe, Jr. et al. AJ 4,012,524 03-1-77 Cragoe, Jr. et al. AJ 4,012,524 03-1-77 Cragoe, Jr. et al. AK 4,159,279 06-26-79 Smith et al. AK 4,159,279 06-26-79 Smith et al. AM 4,163,781 08-07-79 Cragoe, Jr. et al. AN 4,085,219 04-18-78 Cragoe, Jr. et al. AN 4,000 DOUMENT NUMBER DATE COUNTRY TRANSLATION YES NO ADMINISTRATION OF APP APPENDENT OCUMENTS OCUMENT NUMBER DATE COUNTRY TRANSLATION YES NO APP APPENDENT OCUMENTS TRANSLATION APP APP APPENDENT OCUMENTS APP APPENDENT OCUMENTS TRANSLATION APP APP APPENDENT OCUMENTS APP APP APPENDENT OCUMENTS APP APP APP APP APP APP APP APP APP AP | | | | DATE | N | IAME | CLASS | | | |
| AC 3,864,401 02-04-75 Schultz et al. AD 3,914,253 10-21-75 Cragoe, Jr. et al. AE 3,929,872 12-30-75 Cragoe, Jr. et al. AF 3,931,239 01-06-76 Cragoe, Jr. et al. AF 3,931,239 01-06-76 Cragoe, Jr. et al. AG 3,953,476 04-27-76 Cragoe, Jr. et al. AH 3,966,966 06-29-76 Cragoe, Jr. et al. AI 4,006,180 02-01-77 Cragoe, Jr. et al. AJ 4,012,524 03-15-77 Cragoe, Jr. et al. AK 4,159,279 06-26-79 Smith et al. AL 4,163,781 08-07-79 Cragoe, Jr. et al. AN 4,085,219 04-18-78 Cragoe, Jr. et al. AN 4,085,219 04-18-78 Cragoe, Jr. et al. AN 4,085,219 04-18-78 Cragoe, Jr. et al. AN 7,000 DOUMENT DATE COUNTRY FOREIGN PATENT DOCUMENTS COUNTRY TRANSLATION YES NO AP AP AP AP AP AP AP APPLIED | | AA | 4,177,285 | 12-04-79 | Cragoe, Jr. et al. | | | | | |
| AD 3,914,253 10-21-75 Cragoe, Jr. et al. | | AB | 3,794,734 | 02-26-74 | Cragoe, Jr. et al. | | | | | |
| AE 3,929,872 12-30-75 Cragoe, Jr. et al. | | AC | 3,864,401 | 02-04-75 | Schultz et al. | | | | | |
| AF 3,931,239 | | AD | 3,914,253 | 10-21-75 | Cragoe, Jr. et al. | | | | | |
| AG 3,953,476 04-27-76 Cragoe, Jr. et al. | | ΑE | 3,929,872 | 12-30-75 | Cragoe, Jr. et al. | | | | | |
| AH 3,966,966 06-29-76 Cragoe, Jr. et al. | | AF | 3,931,239 | 01-06-76 | Cragoe, Jr. et al. | | | | | |
| Al 4,006,180 02-01-77 Cragoe, Jr. et al. | | AG | 3,953,476 | 04-27-76 | Cragoe, Jr. et al. | | | | | |
| AJ 4,012,524 03-15-77 Cragoe, Jr. et al. AK 4,159,279 06-26-79 Smith et al. AL 4,163,781 08-07-79 Cragoe, Jr. et al. AM 4,163,794 08-07-79 Cragoe, Jr. et al. AM 4,163,794 08-07-79 Cragoe, Jr. et al. AN 4,085,219 04-18-78 Cragoe, Jr. et al. FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY TRANSLATION YES NO AO AP AP AQ | | АН | 3,966,966 | 06-29-76 | Cragoe, Jr. et al. | | | | | |
| AK | | Al | 4,006,180 | 02-01-77 | Cragoe, Jr. et al. | | | | | |
| AL 4,163,781 08-07-79 Cragoe, Jr. et al. AM 4,163,794 08-07-79 Cragoe, Jr. et al. AN 4,085,219 04-18-78 Cragoe, Jr. et al. FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY TRANSLATION YES NO AQ A | | AJ | 4,012,524 | 03-15-77 | Cragoe, Jr. et al. | | | | | |
| AM 4,163,794 08-07-79 Cragoe, Jr. et al. AN 4,085,219 04-18-78 Cragoe, Jr. et al. FOREIGN PATENT DOCUMENTS TRANSLATION YES NO AO AP AP AR AR AT AT A AU AND APPLIED APPLIE | | AK | 4,159,279 | 06-26-79 | Smith et al. | | | | | |
| AN 4,085,219 OH-18-78 FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY TRANSLATION YES NO AO AP AQ AR AR AS AS AT AU AV OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) R. Tarran et al., The CF Salt Controversy: In Vivo Observations and Therapeutic Approaches, Molecular Cell, Vol. 8, 149-158, July 2001. AX Michael R. Knowles et al., Amiloride in Cystic Fibrosis: Safety, Pharmacokinetics, and Efficacy in the Treatment of Pulmonary Disease, Chapter 20, page 301-316. AY Louis Simchowitz et al., An Overview of the Structure Activity Relations in the Amiloride Series, Chapter 2, page 9-25. AZ J.R. Sabater et al., Aerosolization of P2v2-Receptor Agonists Enhances Mucociliary Clearance in Sheep, The American Physiological Society, page 2191-2196. Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in | | AL | 4,163,781 | 08-07-79 | Cragoe, Jr. et al. | | 1 | | | |
| FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY TRANSLATION YES NO AO AP AP AQ AR AS AS AT AU AV OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) R. Tarran et al., The CF Salt Controversy: In Vivo Observations and Therapeutic Approaches, Molecular Cell, Vol. 8, 149-158, July 2001. AX Michael R. Knowles et al., Amiloride in Cystic Fibrosis: Safety, Pharmacokinetics, and Efficacy in the Treatment of Pulmonary Disease, Chapter 20, page 301-316. AY Louis Simchowitz et al., An Overview of the Structure Activity Relations in the Amiloride Series, Chapter 2, page 9-25. AZ J.R. Sabater et al., Aerosolization of P2v2-Receptor Agonists Enhances Mucociliary Clearance in Sheep. The American Physiological Society, page 2191-2196. Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in | | AM | 4,163,794 | 08-07-79 | Cragoe, Jr. et al. | | | İ | | |
| DOCUMENT NUMBER DATE COUNTRY TRANSLATION YES NO AO AP AQ AQ AR AR AS AT AU AV OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) R. Tarran et al., The CF Salt Controversy: In Vivo Observations and Therapeutic Approaches, Molecular Cell, Vol. 8, 149-158, July 2001. R. Tarran et al., The CF Salt Controversy: In Vivo Observations and Therapeutic Approaches, Molecular Cell, Vol. 8, 149-158, July 2001. AX Michael R. Knowles et al., Amiloride in Cystic Fibrosis: Safety, Pharmacokinetics, and Efficacy in the Treatment of Pulmonary Disease, Chapter 20, page 301-316. AY J.R. Sabater et al., Aerosolization of P2y2-Receptor Agonists Enhances Mucocilitary Clearance in Sheep, The American Physiological Society, page 2191-2196. Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in | | AN | 4,085,219 | 04-18-78 | Cragoe, Jr. et al. | | | | | |
| NUMBER AO AO AO AP AQ AQ AR AS AT AT AU AV CHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) R. Tarran et al., The CF Salt Controversy: In Vivo Observations and Therapeutic Approaches, Molecular Cell, Vol. 8, 149-188, July 2001. AX Michael R. Knowles et al., Amiloride in Cystic Fibrosis: Safety, Pharmacokinetics, and Efficacy in the Treatment of Pulmonary Disease, Chapter 20, page 301-316. AY Louis Simchowitz et al., An Overview of the Structure Activity Relations in the Amiloride Series, Chapter 2, page 9-25. AZ J.R. Sabater et al., Aerosolization of P2v2-Receptor Agonists Enhances Mucociliary Clearance in Sheep, The American Physiological Society, page 2191-2196. Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in | | - | | FO | REIGN PATENT [| OCUMENTS | | | | |
| AP AQ AQ AR | | Ι Ι Ι Ι ΙΔΙΕ | | | COUNTRY | | | | | |
| AQ AR AR AS AS AT AU AU AV | | AO | | | | | | | | |
| AR AS AS AT AT AT A AN AVAILABLE AND | | AP | | | | • | | | | |
| AS AT AT AU AU AV | | AQ | | | | | | | | |
| AT AU AU AV | | AR | | | | | | | | |
| AU AV OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) R. Tarran et al., The CF Salt Controversy: In Vivo Observations and Therapeutic Approaches, Molecular Cell, Vol. 8, 149-158, July 2001. AX Michael R. Knowles et al., Amiloride in Cystic Fibrosis: Safety, Pharmacokinetics, and Efficacy in the Treatment of Pulmonary Disease, Chapter 20, page 301-316. AY Louis Simchowitz et al., An Overview of the Structure Activity Relations in the Amiloride Series, Chapter 2, page 9-25. AZ J.R. Sabater et al., Aerosolization of P2y2-Receptor Agonists Enhances Mucociliary Clearance in Sheep, The American Physiological Society, page 2191-2196. Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in | | AS | | | | | | | | |
| OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) R. Tarran et al., The CF Salt Controversy: In Vivo Observations and Therapeutic Approaches, Molecular Cell, Vol. 8, 149-158, July 2001. Michael R. Knowles et al., Amiloride in Cystic Fibrosis: Safety, Pharmacokinetics, and Efficacy in the Treatment of Pulmonary Disease, Chapter 20, page 301-316. Louis Simchowitz et al., An Overview of the Structure Activity Relations in the Amiloride Series, Chapter 2, page 9-25. AZ J.R. Sabater et al., Aerosolization of P2y2-Receptor Agonists Enhances Mucociliary Clearance in Sheep, The American Physiological Society, page 2191-2196. Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in | | AT | | | | | | | | |
| OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) R. Tarran et al., The CF Salt Controversy: In Vivo Observations and Therapeutic Approaches, Molecular Cell, Vol. 8, 149-158, July 2001. AX Michael R. Knowles et al., Amiloride in Cystic Fibrosis: Safety, Pharmacokinetics, and Efficacy in the Treatment of Pulmonary Disease, Chapter 20, page 301-316. AY Louis Simchowitz et al., An Overview of the Structure Activity Relations in the Amiloride Series, Chapter 2, page 9-25. AZ J.R. Sabater et al., Aerosolization of P2y2-Receptor Agonists Enhances Mucociliary Clearance in Sheep, The American Physiological Society, page 2191-2196. Examiner Date Considered *Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in | | AU | | | 1 | | | | | |
| AW R. Tarran et al., The CF Salt Controversy: In Vivo Observations and Therapeutic Approaches, Molecular Cell, Vol. 8, 149-158, July 2001. Michael R. Knowles et al., Amiloride in Cystic Fibrosis: Safety, Pharmacokinetics, and Efficacy in the Treatment of Pulmonary Disease, Chapter 20, page 301-316. Louis Simchowitz et al., An Overview of the Structure Activity Relations in the Amiloride Series, Chapter 2, page 9-25. AZ J.R. Sabater et al., Aerosolization of P2v2-Receptor Agonists Enhances Mucociliary Clearance in Sheep, The American Physiological Society, page 2191-2196. Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in | | AV | | | | | | | | |
| AW 158, July 2001. AX Michael R. Knowles et al., Amiloride in Cystic Fibrosis: Safety, Pharmacokinetics, and Efficacy in the Treatment of Pulmonary Disease, Chapter 20, page 301-316. AY Louis Simchowitz et al., An Overview of the Structure Activity Relations in the Amiloride Series, Chapter 2, page 9-25. AZ J.R. Sabater et al., Aerosolization of P2y2-Receptor Agonists Enhances Mucociliary Clearance in Sheep, The American Physiological Society, page 2191-2196. Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in | | | OTHER REF | ERENCES (| Including Author | , Title, Date, Pertinen | t Pages, e | etc.) | | |
| AX Pulmonary Disease, Chapter 20, page 301-316. Louis Simchowitz et al., An Overview of the Structure Activity Relations in the Amiloride Series, Chapter 2, page 9-25. AZ J.R. Sabater et al., Aerosolization of P2y2-Receptor Agonists Enhances Mucociliary Clearance in Sheep, The American Physiological Society, page 2191-2196. Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in | | AW | | Salt Controv | ersy: In Vivo Obs | ervations and Therape | eutic Appro | paches, Mo | olecular | Cell, Vol. 8, 149- |
| AY J.R. Sabater et al., <u>Aerosolization of P2y2-Receptor Agonists Enhances Mucociliary Clearance in Sheep</u> , <i>The American Physiological Society</i> , page 2191-2196. Examiner Date Considered *Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in | | AX | | | | Safety, Pharmacokine | etics, and l | Efficacy in | the Trea | atment of |
| AZ Physiological Society, page 2191-2196. Examiner Date Considered *Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in | | | | | | | | | | , page 9-25. |
| *Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in | | | | | | | | | | The American |
| | Examiner | | | | | | Date Cor | nsidered | | |
| conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | 09; Draw I | ine through | citation | n if not in |

| | | | | | | Taravis | | | |
|--|-----------|---|--|--|----------------------|--|---------------------------------------|--|--|
| (Modified) PATENT AND TRADEMARK OFFICE | | | ATTY DOCKET NO. 251529US96DIV | SERIAL NO. New Application | | | | | |
| | | | APPLICANT Michael R. JOHNSON | | | | | | |
| | | | | FILING DATE Herewith | | GROUP | | | |
| | | | U | S. PATENT DOCUMENTS | | 1 | | | |
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE | | |
| ITTIAL | AA | 4,025,625 | 05-24-77 | Rooney et al. | | CLASS | IF AFFROFRIATE | | |
| - | AB | 4,196,292 | 04-01-80 | Woltersdorf, Jr. et al. | + | | · · · · · · · · · · · · · · · · · · · | | |
| | AC | 4,087,526 | 05-02-78 | Cragoe, Jr. et al. | | | | | |
| | AD | 4,087,542 | 05-02-78 | Cragoe, Jr. et al. | | | | | |
| | AE | 4,092,414 | 05-30-78 | Cragoe, Jr. et al. | | | | | |
| | AF | 4,100,294 | 07-11-78 | Cragoe, Jr. et al. | + | | | | |
| | AG | 4,105,769 | 08-08-78 | Rooney et al. | + | | | | |
| | AH | 4,140,776 | | Cragoe, Jr. et al. | + | | | | |
| | Al | 4,145,551 | 03-20-79 | Cragoe, Jr. et al. | - | | | | |
| | AJ | 4,181,727 | | Cragoe, Jr. et al. | | | | | |
| | AK | 4,237,130 | 12-02-80 | Cragoe, Jr. et al. | - | | ····· | | |
| | AL | 4,237,144 | 12-02-80 | Cragoe, Jr. et al. | <u> </u> | | | | |
| | AM | 4,277,602 | 07-07-81 | Woltomdorf et al | | | | | |
| | AN | 4,291,050 | 09-22-81 | Woltersdorf, Jr. et al. | | | | | |
| | 1 / | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | | EIGN PATENT DOCUMENTS | _1 | 1 | | | |
| | | DOCUMENT | | | | Т | RANSLATION | | |
| | | NUMBER | DATE | COUNTRY | | YES | NO | | |
| | AO | | | | | | | | |
| | AP | | | | | \ <u>-</u> | | | |
| | AQ AR | | | | | <u> </u> | | | |
| | AS | | | <u> </u> | | | | | |
| | AT | | | | | | | | |
| * | AU | | | | | | | | |
| | ΑV | | | | | | | | |
| | | OTHER RE | FERENCES | (Including Author, Title, Date, Pertino | ent Pages, et | c.) | | | |
| | AW | Thomas R. Kleyman et a | I., Amiloride | and Its Analogs as Tools in the Study of | | | al of Membrane | | |
| | | Biology, voi. 105, pages | <i>Biology</i> , Vol. 105, pages 1-21, 1988. | | | | | | |
| | AX | Edward C. Taylor et al., | A Facile Rou | te to "Open Chain" Analogues of DDA | <u>ГНF,</u> Heterocy | cles, Vol. 28 | , No. 2, 1989. | | |
| | AY | Paul-Michael Windscheit 87-92, January 1994. | fet al., <u>Subs</u> | tituted Dipyridlethenes and -ethynes an | d Key Pyridin | e Building Blo | ocks, Synthesis, pages | | |
| | AZ | Edward J. Cragoe, Jr., <u>T</u> | he Synthesis | s of Amiloride and Its Analogs, page 24 | -38, Chapter (| 3. | | | |
| Examiner | | | - | | Date Con | sidered | | | |
| | I=:4: - 1 | if makes and in the second | | han as mak alkaktan in ta ananga | | | | | |
| | | | | her or not citation is in conformar Include copy of this form with ne | | | | | |

| Form PTO 1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE | | | ATTY DOCKET NO. 251529US96DIV | SERIAL NO. New Application | | | | |
|--|--|----------------------------|----------------------------------|---|------------|---------------------------------------|-------------------------------|--|
| LIST OF | REFE | RENCES CITED BY APPI | LICANT | APPLICANT Michael | R. JOH | NSON | | |
| | | | | FILING DATE Herewith | | GROUP | | |
| | | | 1 | U.S. PATENT DOCUMENTS | | | | |
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE | |
| | AA | 4,003,927 | 01-18-77 | Woltersdorf, Jr. et al. | | | | |
| | AB | 4,296,122 | 10-20-81 | Cragoe, Jr. et al. | | | | |
| | AC | 4,317,822 | 03-02-82 | Woltersdorf, Jr. et al. | | | | |
| | AD | 4,362,724 | 12-07-82 | Bock et al. | | | | |
| | ΑE | 4,401,669 | 08-30-83 | Cragoe, Jr. et al. | | | | |
| | AF | 3,974,212 | 08-10-76 | Cragoe, Jr. et al. | | | | |
| | AG | 3,984,465 | 10-05-76 | Cragoe, Jr. et al. | | | | |
| | АН | 3,984,552 | 10-05-76 | Cragoe, Jr. et al. | | | | |
| | Al | 4,067,980 | 01-10-78 | Cragoe, Jr. et al. | | | | |
| | AJ | 4,085,117 | 04-18-78 | Cragoe, Jr. et al. | 1 | | | |
| | AK | 4,085,211 | 04-18-78 | Cragoe, Jr. et al. | | | | |
| | AL | 4,246,406 | 01-20-81 | Cragoe, Jr. et al. | | | | |
| | АМ | 3,472,848 | 10-14-69 | Edward J. Cragoe, Jr. et al. | | | | |
| | AN | 3,544,571 | 12-01-70 | Edward J. Cragoe, Jr., et al. | | · · · · · · · · · · · · · · · · · · · | | |
| | L | J | FO | REIGN PATENT DOCUMENTS | - ! | 1 | | |
| | | DOCUMENT NUMBER | DATE | COUNTRY | | YE | TRANSLATION S NO | |
| | AO | | | | | | | |
| | AP | | | | | <u> </u> | | |
| | AQ | | 1 | | | 1 | | |
| | AR | | | | | <u> </u> | | |
| | AS | | | | | | | |
| | AT | | | | | † | | |
| | AU | | | | | | | |
| | AV | | <u> </u> | | | - | | |
| | ı | OTHER REF | ERENCES (| Including Author, Title, Date, Pertine | nt Pages 4 | atc) | | |
| | AW | Jack H. Li, et al., Stereo | selective Blo | ckage of Amphibian Epithelial Sodium (erapeutics, Vol. 267, No. 3, pages 1081 | Channels b | y Amiloride | e Analogs, The Journal of | |
| | Pallav L. Shah, M.D., <u>Chapter 7. Progress in the Treatment of Pulmonary Disease in Cystic Fibrosis</u> , Annual Reports in Medicinal Chemistry, Vol. 36, pages 67-76, 2001. | | | | | | | |
| | AY | | | duced Mucus Oxygen Concentration in nical Investigation, February 2002, Volume | | | | |
| | AZ | Edward J. Cragoe, Jr., e | et al., <u>Chapte</u> | r 7: Diuretic Agents, Annual Reports in | Medicinal | Chemistry, | 1966, page 59-68. | |
| Examiner | | • | | 1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1- | Date Co | nsidered | | |
| | | | | t citation is in conformance with MPEP | 09; Draw | line throug | h citation if not in | |
| conformance | and no | ot considered. Include cor | y of this forn | with next communication to applicant. | | | | |

| Form PTO 1449 (Modified) | | | ATTY DOCKET NO. 251529US96DIV | | | SERIAL NO. New Application | | | |
|-----------------------------|------------|---|----------------------------------|-------------------------------|----------------|-----------------------------|--------------|----------------------------|--|
| LIST OF | | | APPLICANT | Michael | R. JOHN | NSON | | | |
| | F | | | FILING DATE Herew | vith | | GROUP | | |
| | | | (| U.S. PATENT DOCUMENT | s | | | | |
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | _ | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE | |
| | AA | 3,991,106 | 11-09-76 | Cragoe, Jr., et al. | | | | | |
| | AB | 3,991,087 | 11-09-76 | Cragoe, Jr. et al. | | | | | |
| | AC | 3,989,749 | 11-02-76 | Cragoe, Jr. et al. | | | | | |
| | AD | 3,987,091 | 10-19-76 | Cragoe, Jr. et al. | | | | | |
| | ΑE | 3,979,361 | 09-07-76 | Schultz et al. | | | | | |
| | AF | 3,976,686 | 08-24-76 | Cragoe, Jr. et al. | | | | | |
| | AG | 3,976,681 | 08-24-76 | Cragoe, Jr. et al. | | | | | |
| | АН | 3,958,004 | 05-18-76 | Cragoe, Jr. et al. | · | | | | |
| | Al | 3,956,374 | 05-11-76 | Shepard et al. | | | - | | |
| | AJ | 3,928,624 | 12-23-75 | Cragoe, Jr. et al. | | | | | |
| | AK | 3,894,065 | 07-08-75 | Cragoe, Jr. et al. | | | | | |
| | AL | 3,668,241 | 06-06-72 | Cragoe, Jr. et al. | | | | | |
| | АМ | 3,625,950 | 12-07-71 | Edward J. Cragoe, Jr. | | | | | |
| | AN | 4,298,743 | 11-03-81 | Cragoe, Jr. et al. | | | | | |
| | | - | FO | REIGN PATENT DOCUME | NTS | | | | |
| DOCUMENT DATE | | | COUNTRY | | | TRANSLATION YES NO | | | |
| | AO | | | | | | | | |
| | ΑÞ | | | | | | | | |
| | AQ | | | | | | | | |
| | AR | | | | | | | | |
| | AS | | | | | | | | |
| | AT | • | | | | | | | |
| | ΑU | | | | | | | | |
| | AV | | | | | | | | |
| | | OTHER REF | ERENCES (| Including Author, Title, Da | ate, Pertinen | t Pages, e | tc.) | | |
| | AW | Edward J. Cragoe, Jr., e | t al., <u>Chapte</u> | r 7: Diuretic Agents, Annua | I Reports in M | Medicinal (| chemistry, | 1965, page 67-77. | |
| | AX | Robert L. Smith, et al., <u>C</u> | chapter 8: D | iuretics, Annual Reports in I | Medicinal Che | emistry, Vo | olume 11, p | pages 71-79, 1976. | |
| | AY | Robert L. Smith, et al., <u>C</u> | hapter 7: D | iuretics, Annual Reports in I | Medicinal Ch | emistry, Vo | olume 13, į | pages 61-70, 1978. | |
| | AZ | Edward J. Cragoe, Jr., <u>Structure-Activity Relationships in the Amiloride Series</u> , <i>Merck Sharp and Dohme Research Laboratories</i> , 1979, pages 1-20. | | | | | | | |
| Examiner | <u> </u> | L | | | | Date Cor | nsidered | | |
| *Examiner: In | itial if r | eference is considered, w | hether or no | t citation is in conformance | with MPEP 6 | I 09; Draw li | ne through | n citation if not in | |
| conformance | and no | ot considered. Include cop | y of this form | with next communication t | o applicant. | | - 3 | | |

| Form PTO 1449 (Modified) | | U.S. DEPARTMENT O PATENT AND TRADE | F COMMERCE MARK OFFICE | ATTY DOCKET NO. 251529US96D |)IV | | SERIAL NO. New Application | | |
|-----------------------------|--|---------------------------------------|---------------------------|---|-------------|------------|-----------------------------|----------------------------|--|
| LIST OF | REFE | RENCES CITED BY APP | LICANT | APPLICANT Michael R. JOHNSON | | | | | |
| | | | | FILING DATE Herewith | | | GROUP | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | |
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE | |
| | AA | 3,313,813 | 4/11/67 | Cragoe, Jr., et al. | | | | | |
| | AB | | | | | | | | |
| | AC | | | | | | | | |
| | AD | | ļ | | | | | | |
| | AE | | | | | | | | |
| | AF | | <u> </u> | | | | | | |
| | AG AH | | | | | | | | |
| | Al | | <u> </u> | | | | | | |
| | AJ | | | | | | | | |
| | AK | | | | | | | | |
| | AL | | | | | | | | |
| | AM | | | | | | | | |
| | AN | | | | | | | | |
| | | | FO | REIGN PATENT DOCUMENTS | | | | | |
| | | DOCUMENT NUMBER | DATE | COUNTRY | | | YES | TRANSLATION S NO | |
| | AO | | | | | | | | |
| | AP | | <u> </u> | | | ····· | | | |
| | AQ | | ļ | | | | | | |
| | AR | | | | | | | | |
| | AS AT | | | | | | | | |
| | AU | | <u> </u> | | | | | | |
| | AV | | | | | | | | |
| | | OTHER RE | EDENCES (| Including Author, Title, Date, Pe | 4'4 | D | 4-) | | |
| | AW | T | | Pharmacology, 95(1), pp. 67-76 (I | | | 16.) | | |
| | AX | Thomas R. Kleyman, et | al., America | n Journal of Physiology, 260(2, Pt | t.1), pp. (| C271-C27 | 76 (English |), 1991. | |
| | AY | K.E. Barrett, et al., Annu | ı. Rev. Physi | ol. 2000; 62, pp. 535-572. | | | | | |
| | R.F. Epand, et al., British Journal of Cancer, 63(2), 247-51 (English) 1991. | | | | | | | | |
| Examiner | Mos. | | | | | Date Cons | sidered | | |
| *Examiner: Ini | tial if re | eference is considered, when | her or not cita | tion is in conformance with MPEP 60 ion to applicant. | 09; Draw | line throu | gh citation i | if not in conformance and | |